SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

Ng, Dianna; Goldgof, Gregory M.; Shy, Brian R.; Levine, Andrew G.; Balcerek, Joanna; Bapat, Sagar P.; Prostko, John; Rodgers, Mary A.; Coller, Kelly E.; Pearce, Sandra; Franz, Sergej; Du, Li; Stone, Mars; Pillai, Satish K.; Sotomayor-González, Alicia; Servellita, Venice; Martin, Carolyn; Granados, Andrea; Glasner, Dustin R.; Han, Lucy; Truong, Kent; Akagi, Naomi; Nguyen, David N.; Neumann, Neil M.; Qazi, Daniel; Hsu, Elaine; Gu, Wei; Santos, Yale A.; Custer, Brian; Green, Valerie; Williamson, Phillip; Hills, Nancy K.; Lu, Chuanyi M.; Whitman, Jeffrey D.; Stramer, Susan L.; Wang, Candace; Reyes, Kevin; Hakim, Jill; Sujishi, Kirk; Alazzeh, Fariba; Pharm, Lori; Oon, Ching-Ying; Miller, Steve; Kurtz, Theodore W.; Hackett, John; Simmons, Graham; Busch, Michael P.; Chiu, Charles Y.

doi:10.1101/2020.05.19.20107482

Cited by 67 publications

(75 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From our analysis of 1347 specimens, the sensitivity of IgG assay increased weekly to reach 99.6% at 4-5 weeks after symptom onset. The observed sensitivity of 93.6% at 15-21 days following symptom onset is consistent with previous studies [ 15 , 16 ], but lower than what is claimed in the manufacturer’s package insert. The difference may be attributed in part to the patient population used for this study, in which the majority was hospitalized with multiple comorbidities.…”

Section: Discussionsupporting

confidence: 91%

Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect

Maine

Lao

Krishnan

et al. 2020

Journal of Clinical Virology

View full text Add to dashboard Cite

Highlights The Abbott IgM assay against SARS-CoV-2 is detected slightly earlier compared to IgG. Both Abbott IgM and IgG assays exhibit excellent sensitivity and specificity. Positive rate of IgM drops to 30.8% after 3 months of symptoms, in contrast to IgG which is sustained in 92.3% patients 3-6 months post symptom onset. In symptomatic patients who test negative by PCR for a SARS-CoV-2 infection, assessing IgM and IgG antibodies can aid in supporting a diagnosis of COVID-19.

show abstract

Section: Discussionsupporting

confidence: 91%

Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect

Maine

Lao

Krishnan

et al. 2020

Journal of Clinical Virology

View full text Add to dashboard Cite

show abstract

“…Macaque IgA antibodies were detected with the antibodies described below. IgG, IgM or IgA antibodies had to be increased 3-fold over the day 0 value to be considered significant ELISA for SARS-specific IgA and antibodies to RBD These assays were done using methods similar to those described (52) Neutralizing assay Pseudovirus neutralization assay was performed as described (53).…”

Section: While It Remains Unknown Whether Immune Responses Elicited Wmentioning

confidence: 99%

SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques

Elizaldi

Lakshmanappa

Roh

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

ABSTRACTCD4 T follicular helper (Tfh) cells are important for the generation of long-lasting and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates Tfh cells and stimulates the germinal center response is an important question as we investigate vaccine options for the current pandemic. Here we report that, following infection with SARS-CoV-2, adult rhesus macaques exhibited transient accumulation of activated, proliferating Tfh cells in their peripheral blood on a transitory basis. The CD4 helper cell responses were skewed predominantly toward a Th1 response in blood, lung, and lymph nodes, reflective of the interferon-rich cytokine environment following infection. We also observed the generation of germinal center Tfh cells specific for the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, and a corresponding early appearance of antiviral serum IgG antibodies but delayed or absent IgA antibodies. Our data suggest that a vaccine promoting Th1-type Tfh responses that target the S protein may lead to protective immunity.

show abstract

“…Numerous serological surveys conducted in affected countries at the beginning of the COVID-19 epidemic indicate that nationwide antibody prevalence varies between 1-10%, with peaks around 10-15% in heavily affected urban areas [5]. Most of the serological studies already available have been carried out in continental Europe [6][7][8][9][10][11][12] and in the United States [13][14][15][16] . Although Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted across the continent, meaning the underlying level of infection remains largely unknown [5,17,18].…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana

Flamand

Enfissi

Bailly

et al. 2020

Preprint

View full text Add to dashboard Cite

Background SARS-CoV-2 seroprevalence studies are crucial for clarifying dynamics in affected countries and determining the route that has already been achieved towards herd immunity. While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there. Methods A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 in 4 medical biology laboratories and 5 health centers of French Guiana, representing a period shortly after the epidemic peak. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. Results The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p=0.19) or age (p=0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Conclusions Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by the young population structure.

show abstract

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

Cited by 67 publications

References 13 publications

Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect

Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect

SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques

Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana

Contact Info

Product

Resources

About